Effect of zoledronic acid on mandibular socket healing process of mice at an early stage

doi:10.19439/j.sjos.2022.04.003

Abstract

Abstract: PURPOSE: To investigate how bisphosphonates affect early process of socket healing in mice model. METHODS: Eighteen 8-9 weeks C57BL/6 male mice were randomly divided into control and experimental group. Bisphosphonate-related osteonecrosis of the jaw（BRONJ）model was conducted by intraperitoneal injection of zoledronate（ZOL） and extraction of lower left first molar in mice. Three, five, seven day after surgery, the mice were sacrificed and paraffin-embedded slides were made. H-E staining was used to evaluate the gross condition. The distribution and amounts of osteoclasts were measured by TRAP staining. Finally, immunochemical staining was used to detect RUNX2 and CTSK level. All experiments were duplicated thrice, ImageJ was used for transformation of pictures and SPSS 20.0 software package was used for statistical analysis. RESULTS: In comparison with the control group, early process of socket healing in the experimental group was generally delayed. RUNX2,CTSK,TRAP expression level was decreased. On the whole, early bone remodeling process in ZOL injection group was suppressed. CONCLUSIONS: Zoledronic acid inhibited the migration of fibroblasts into socket, and reduced the expression of Runx2, hindering new bone formation. It also can reduce the expression of TRAP 3,5,7 days after tooth extraction and CTSK expression three days after operation, thus inhibiting the bone resorption function of osteoclasts.

Key words: Bisphosphonate-related osteonecrosis of the jaws, Socket healing, Zoledronate

CLC Number:

R782

JIANG Run-yang, KANG Fei-wu. Effect of zoledronic acid on mandibular socket healing process of mice at an early stage[J]. Shanghai Journal of Stomatology, 2022, 31(4): 349-353.

References

[1] Ruggiero S, Woo V, Mehrotra B, et al.Osteonecrosis of the jaws associated with the use of bisphosphonate medications: a report of 60 cases[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2004, 98(2): 196-197.
[2] Marx RE, Sawatari Y, Fortin M, et al.Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment[J]. J Oral Maxillofac Surg, 2005,63(11): 1567-1575.
[3] Watters AL, Hansen HJ, Williams T, et al.Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(2): 192-200.
[4] Jann J, Gascon S, Roux S, et al. Influence of the TGF-β superfamily on osteoclasts/osteoblasts balance in physiological and pathological bone conditions[J]. Int J Mol Sci, 2020, 21(20): 7597.e1-7597.e54.
[5] Lai K, Xi Y, Du X, et al. Activation of Nell-1 in BMSC sheet promotes implant osseointegration through regulating Runx2/Osterix axis[J]. Front Cell Dev Biol, 2020, 8: 868.e1-868.e11.
[6] Khosla S, Burr D, Cauley J, et al.Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research[J]. J Bone Miner Res, 2007, 22(10): 1479-1491.
[7] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update[J]. J Oral Maxillofac Surg, 2014,72(10):1938-1956.
[8] Badros A, Weikel D, Salama A, et al.Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors[J]. J Clin Oncol, 2006, 24(6): 945-952.
[9] Demircan S, Isler SC.Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: a case control study[J]. Niger J Clin Pract, 2020, 23(2): 154-158.
[10] Gao SY, Lin RB, Huang SH, et al.PDGF-BB exhibited therapeutic effects on rat model of bisphosphonate-related osteonecrosis of the jaw by enhancing angiogenesis and osteogenesis[J]. Bone, 2021,144: 115117.
[11] Wei X, Pushalkar S, Estilo C, et al.Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw[J]. Oral Dis, 2012, 18(6): 602-612.
[12] English BC, Baum CE, Adelberg DE, et al.A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer[J]. Ther Clin Risk Manag, 2010, 6: 579-583.
[13] Kuroshima S, Sasaki M, Sawase T.Medication-related osteonecrosis of the jaw: a literature review[J]. J Oral Biosci, 2019, 61(2): 99-104.
[14] Dong W, Qi M, Wang Y, et al.Zoledronate and high glucose levels influence osteoclast differentiation and bone absorption via the AMPK pathway[J]. Biochem Biophys Res Commun, 2018, 505(4): 1195-1202.
[15] 潘剑, 王杞章, 刘济远. 双磷酸盐相关性颌骨坏死[J]. 华西口腔医学杂志, 2017, 35(1): 29-36.
[16] Huang J, Liu L, Jin S, et al.Proanthocyanidins promote osteogenic differentiation of human periodontal ligament fibroblasts in inflammatory environment via suppressing NF-κB signal pathway[J]. Inflammation, 2020, 43(3): 892-902.
[17] Zhao Y, Wang L, Liu Y, et al.Technetium-99 conjugated with methylene diphosphonate ameliorates ovariectomy-induced osteoporotic phenotype without causing osteonecrosis in the jaw[J]. Calcif Tissue Int, 2012, 91(6): 400-408.
[18] Hokugo A, Kanayama K, Sun S, et al.Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice[J]. Bone, 2019, 123: 115-128.